Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TSHA Taysha Gene Therapies, Inc.

Pre-Market Trading 03-26 06:50:36 EDT

1.77

+0.11

+6.63%

High1.78	Low1.63	Vol1.67M
Open1.67	D1 Closing1.66	Amplitude9.04%
Mkt Cap362.85M	Tradable Cap227.54M	Total Shares205.00M
T/O2.84M	T/O Rate1.30%	Tradable Shares128.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"TSHA","market":"US","secType":"STK","nameCN":"Taysha Gene Therapies, Inc.","latestPrice":1.77,"timestamp":1742932800000,"preClose":1.66,"halted":0,"volume":1674410,"delay":0,"floatShares":128554637,"shares":205001632,"eps":-0.357,"marketStatus":"Pre-Market Trading","change":0.11,"latestTime":"03-26 06:50:36 EDT","open":1.67,"high":1.78,"low":1.63,"amount":2839676.290865,"amplitude":0.090361,"askPrice":2.16,"askSize":200,"bidPrice":1.47,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.357,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1742995800000},"marketStatusCode":1,"adr":0,"listingDate":1600920000000,"exchange":"NASDAQ","adjPreClose":1.77,"postHourTrading":{"tag":"盘后","latestPrice":1.7,"preClose":1.77,"latestTime":"19:46 EDT","volume":9568,"amount":16701.448,"timestamp":1742946397418},"volumeRatio":0.8372936694456454,"impliedVol":0.9825,"impliedVolPercentile":0.494},"requestUrl":"/m/hq/s/TSHA","defaultTab":"news","newsList":[{"id":"2517480019","title":"Taysha Gene Therapies announces inducement grant under Nasdaq listing rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480019?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:11","pubTimestamp":1741353080,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (TSHA) announced that, on March 3, 2025, the Compensation Committee of Taysha’s Board of Directors granted three new employee...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-11?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-11?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":[".IXIC","QID","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","TSYW.SI","USJW.SI","BK4112","PSQ","TSHA","TQQQ","QLD","MNQmain","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","USAW.SI","SQQQ","BK4139","NVIW.SI","LU2210150020.SGD","NQmain"],"gpt_icon":0},{"id":"2517808014","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517808014","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517808014?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"DALLAS, March 07, 2025  -- Taysha Gene Therapies, Inc.  , a clinical-stage biotechnology company focused on advancing adeno-associated virus -based gene therapies for severe monogenic diseases of the central nervous system , today announced that, on March 3, 2025, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 225,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635.Company Contact:Hayleigh Collins Senior Director, Corporate Communications & Investor RelationsTaysha Gene Therapies, Inc.hcollins@tayshagtx.com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/taysha-gene-therapies-announces-inducement-130000785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP",".IXIC","LU2210150020.SGD","BK4588","TSHA","IE00BKPKM429.USD","LU2210149790.SGD","BK4112","CNS","IE00B3QW5Z07.USD","BK4585","NDAQ","BK4135","BK4139","IE00BGHQF748.EUR","LU2095319765.USD"],"gpt_icon":0},{"id":"2516689995","title":"Buy Rating Reiterated for Taysha Gene Therapies Amid Positive Clinical Data and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2516689995","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516689995?lang=en_us&edition=full_marsco","pubTime":"2025-03-02 02:05","pubTimestamp":1740852336,"startTime":"0","endTime":"0","summary":"In a report released on February 27, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report),...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-for-taysha-gene-therapies-amid-positive-clinical-data-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-for-taysha-gene-therapies-amid-positive-clinical-data-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"gpt_icon":0},{"id":"2514367175","title":"Taysha Gene Therapies’ Positive Earnings Call Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2514367175","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514367175?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 10:49","pubTimestamp":1740710977,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (($TSHA)) has held its Q4 earnings call. Read on for the main highlights of the call. Taysha Gene Therapies’ recent ear...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-positive-earnings-call-highlights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-positive-earnings-call-highlights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"gpt_icon":0},{"id":"2514740138","title":"Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2514740138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514740138?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 18:37","pubTimestamp":1740652664,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), with a price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-taysha-gene-therapies-buy-rating-backed-by-fda-progress-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-taysha-gene-therapies-buy-rating-backed-by-fda-progress-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","TSHA"],"gpt_icon":0},{"id":"2514187767","title":"Taysha Gene Therapies Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2514187767","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514187767?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 18:17","pubTimestamp":1740651453,"startTime":"0","endTime":"0","summary":"NasdaqGS:TSHA Earnings and Revenue Growth February 27th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 1.1%. Earnings per share  also surpassed analyst estimates by 4.6%.Looking ahead, revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are down 1.2% from a week ago.It is worth noting though that we have found 2 warning signs for Taysha Gene Therapies that you need to take into consideration.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/taysha-gene-therapies-full-2024-101733756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSHA"],"gpt_icon":0},{"id":"2514844543","title":"Q4 2024 Taysha Gene Therapies Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2514844543","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514844543?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 14:04","pubTimestamp":1740636255,"startTime":"0","endTime":"0","summary":"Hayleigh Collins; Director, Head of Corporate Communications and Investor Relations; Taysha Gene Therapies Inc. Ladies and gentlemen, good morning and welcome to the Taysha Gene Therapies full year 2024 conference call. . As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Hayleigh Collins, Director, Head of corporate communications and Investor relations. Please go ahead.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-taysha-gene-therapies-060415944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSHA"],"gpt_icon":0},{"id":"2514684661","title":"Taysha Gene Therapies Reports 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514684661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514684661?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 12:46","pubTimestamp":1740631606,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. ( ($TSHA) ) has released its Q4 earnings. Here is a breakdown of the information Taysha Gene Therapies, Inc. presented ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-reports-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-reports-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA","BK4139"],"gpt_icon":0},{"id":"2514936892","title":"Taysha Gene Therapies Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2514936892","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514936892?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 06:59","pubTimestamp":1740610740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TSHA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 17:59 ET (22:59 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"gpt_icon":0},{"id":"2514286489","title":"Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2514286489","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514286489?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 03:36","pubTimestamp":1740598619,"startTime":"0","endTime":"0","summary":"Analyst Gil Blum of Needham maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), retaining the price target of $6.00. Gil Blu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-taysha-gene-therapies-promising-developments-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-taysha-gene-therapies-promising-developments-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TSHA"],"gpt_icon":0},{"id":"2514435855","title":"Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2514435855","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514435855?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 22:32","pubTimestamp":1740580340,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings SummaryTaysha Gene Therapies Inc TSHA.OQ reported a quarterly adjusted loss of 7 cents per share for the quarter ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nL5N3PH1W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"gpt_icon":0},{"id":"2514778852","title":"Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514778852","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514778852?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 22:15","pubTimestamp":1740579305,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc.  came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of $0.08 per share when it actually produced a loss of $0.09, delivering a surprise of -12.50%.Taysha Gene Therapies , which belongs to the Zacks Medical - Generic Drugs industry, posted revenues of $2.02 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 6.42%. This compares to year-ago revenues of $3.6 million. The company has topped consensus revenue estimates just once over the last four quarters.Taysha Gene Therapies shares have lost about 1.7% since the beginning of the year versus the S&P 500's gain of 1.3%.While Taysha Gene Therapies has underperformed the market so far thi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/taysha-gene-therapies-inc-tsha-141505681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSHA"],"gpt_icon":0},{"id":"2514001832","title":"Taysha Gene Therapies Q4 EPS $(0.07) Beats $(0.08) Estimate, Sales $2.02M Miss $2.31M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2514001832","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514001832?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:04","pubTimestamp":1740575083,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 107.61 percent decrease over earnings of $0.92 per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43970761/taysha-gene-therapies-q4-eps-0-07-beats-0-08-estimate-sales-2-02m-miss-2-31m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Taysha Gene Therapies Q4 EPS $(0.07) Beats $(0.08) Estimate, Sales $2.02M Miss $2.31M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"gpt_icon":1},{"id":"2514832411","title":"Press Release: Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514832411","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514832411?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:00","pubTimestamp":1740574800,"startTime":"0","endTime":"0","summary":"High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated  across both REVEAL trials as of February 2025 data cutoff. Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Part B trial. Productive ongoing discussions with the FDA to solidify regulatory pathway for TSHA-102; update on pivotal trial design expected in H1 2025. Clinical data from cohort two  and cohort one  of both REVEAL trials expected in H1 2025. Conference call and live webcast today at 8:30 AM Eastern Time. DALLAS, Feb. 26, 2025  -- Taysha Gene Therapies, Inc.  , a clinical-stage biotechnology company focused on advancing adeno-associated virus -based gene therapies for severe monogenic diseases of the central nervous system , today reported financial results for the full year ended December 31, 2024, and provided a corporate up","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139","BK4135","CNS"],"gpt_icon":0},{"id":"2513729405","title":"Taysha Gene Therapies Inc  expected to post a loss of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513729405?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:34","pubTimestamp":1740404058,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies Inc  expected to post a loss of8cents a share - Earnings Preview Taysha Gene Therapies Inc TSHA.OQ TSHA.O is expected to show a fall in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL5N3PF17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"gpt_icon":0},{"id":"2512073101","title":"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26","url":"https://stock-news.laohu8.com/highlight/detail?id=2512073101","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512073101?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 21:00","pubTimestamp":1739970000,"startTime":"0","endTime":"0","summary":"DALLAS, Feb.  19, 2025  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies fo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/19/3028733/0/en/Taysha-Gene-Therapies-to-Release-Full-Year-2024-Financial-Results-and-Host-Conference-Call-and-Webcast-on-February-26.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HST","TSHA","BK4588","CNS","BK4135","BK4585","BK4218","BK4181"],"gpt_icon":0},{"id":"2509748014","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509748014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509748014?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 21:00","pubTimestamp":1738933201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nTUA53KD1J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TSHA"],"gpt_icon":0},{"id":"2509837745","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509837745","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509837745?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 21:00","pubTimestamp":1738933200,"startTime":"0","endTime":"0","summary":"DALLAS, Feb.  07, 2025  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/07/3022749/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","BK4585","CNS","LU2095319765.USD","LU2210149790.SGD","BK4588","BK4135","IE00BKPKM429.USD","TSHA","IE00BGHQF748.EUR",".IXIC","NDAQ","IE00B64PRP62.GBP","BK4112"],"gpt_icon":0},{"id":"2501280703","title":"Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2501280703","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501280703?lang=en_us&edition=full_marsco","pubTime":"2025-01-06 19:51","pubTimestamp":1736164260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TSHA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2025 06:51 ET (11:51 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tayshagtx.com","stockEarnings":[{"period":"1week","weight":0.0172},{"period":"1month","weight":0.0994},{"period":"3month","weight":-0.0432},{"period":"6month","weight":-0.1571},{"period":"1year","weight":-0.4216},{"period":"ytd","weight":0.0231}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":-0.0408},{"period":"3month","weight":-0.043},{"period":"6month","weight":0.0055},{"period":"1year","weight":0.1071},{"period":"ytd","weight":-0.0181}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.177294},{"month":2,"riseRate":0.4,"avgChangeRate":0.109391},{"month":3,"riseRate":0.4,"avgChangeRate":-0.075798},{"month":4,"riseRate":0.25,"avgChangeRate":-0.087217},{"month":5,"riseRate":0.25,"avgChangeRate":-0.029549},{"month":6,"riseRate":0.25,"avgChangeRate":-0.00003},{"month":7,"riseRate":0.5,"avgChangeRate":-0.021321},{"month":8,"riseRate":0.75,"avgChangeRate":0.9233},{"month":9,"riseRate":0,"avgChangeRate":-0.14195},{"month":10,"riseRate":0,"avgChangeRate":-0.151796},{"month":11,"riseRate":0.6,"avgChangeRate":0.174321},{"month":12,"riseRate":0.6,"avgChangeRate":-0.073382}],"exchange":"NASDAQ","name":"Taysha Gene Therapies, Inc.","nameEN":"Taysha Gene Therapies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Taysha Gene Therapies, Inc.,TSHA,Taysha Gene Therapies, Inc.股票,Taysha Gene Therapies, Inc.股票老虎,Taysha Gene Therapies, Inc.股票老虎国际,Taysha Gene Therapies, Inc.行情,Taysha Gene Therapies, Inc.股票行情,Taysha Gene Therapies, Inc.股价,Taysha Gene Therapies, Inc.股市,Taysha Gene Therapies, Inc.股票价格,Taysha Gene Therapies, Inc.股票交易,Taysha Gene Therapies, Inc.股票购买,Taysha Gene Therapies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}